Xencor (XNCR) Long-Term Investments (2015 - 2026)
Xencor (XNCR) posted quarterly Long-Term Investments of $157.4 million for Q1 2026, down 42.31% year-over-year from $272.8 million in Q1 2025, and down 10.37% quarter-over-quarter from $175.6 million in Q4 2025.
Analysis
Xencor (XNCR) Long-Term Investments (2015 - 2026) Analysis & Trends
Xencor (XNCR) has reported Long-Term Investments for 12 consecutive years, with $157.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments fell 42.31% year-over-year to $157.4 million; the TTM figure through Mar 2026 stood at $157.4 million (down 42.31% YoY), while the FY2025 annual figure was $175.6 million, down 31.63% from the prior year.
- Long-Term Investments declined to $157.4 million in Q1 2026 per XNCR's latest filing, from $175.6 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $290.3 million in Q3 2024 and bottomed at $31.1 million in Q2 2022.
- Historically, Long-Term Investments has averaged $130.8 million across 5 years, with a median of $64.2 million in 2023.
- Annual changes were most pronounced in 2022 — Long-Term Investments plunged 88.75% — and 2025, when it surged 526.3%.
- Xencor's Long-Term Investments stood at $54.4 million in 2022, then jumped by 167.57% to $145.5 million in 2023, then soared by 76.5% to $256.8 million in 2024, then tumbled by 31.63% to $175.6 million in 2025, then decreased by 10.37% to $157.4 million in 2026.
- Business Quant data shows XNCR's Long-Term Investments at $157.4 million in Q1 2026, $175.6 million in Q4 2025, and $247.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 108.54 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 108.54 Mn |
| Mar 31, 2026 | 157.39 Mn |
| Dec 31, 2025 | 175.60 Mn |
| Sep 30, 2025 | 247.16 Mn |
| Jun 30, 2025 | 260.40 Mn |
| Mar 31, 2025 | 272.82 Mn |
| Dec 31, 2024 | 256.83 Mn |
| Sep 30, 2024 | 290.27 Mn |
| Jun 30, 2024 | 104.86 Mn |
| Mar 31, 2024 | 154.96 Mn |
| Dec 31, 2023 | 145.51 Mn |
| Sep 30, 2023 | 64.21 Mn |
| Jun 30, 2023 | 64.21 Mn |
| Mar 31, 2023 | 54.21 Mn |
| Dec 31, 2022 | 54.38 Mn |
| Sep 30, 2022 | 41.72 Mn |
| Jun 30, 2022 | 140.41 Mn |
| Mar 31, 2022 | 239.04 Mn |
| Dec 31, 2021 | 300.47 Mn |
| Sep 30, 2021 | 276.74 Mn |